Aptamers are single-stranded deoxyribonucleic acid or ribonucleic acid oligonucleotides generated in vitro based on affinity for certain target molecules by a process known as Systematic Evolution of Ligands by Exponential Enrichment. Aptamers can bind their target molecules with high specificity and selectivity by means of structure compatibility, stacking of aromatic rings, electrostatic and van der Waals interactions, and hydrogen bonding. With several advantages over monoclonal antibodies and other conventional small-molecule therapeutics, such as high specificity and affinity, negligible batch to batch variation, flexible modification and stability, lack of toxicity and low immunogenicity, aptamers are becoming promising novel diagnostic and therapeutic agents. This review focuses on the development of aptamers as potential therapeutics for autoimmune diseases, including diabetes mellitus, multiple sclerosis, rheumatoid arthritis, myasthenia gravis, and systemic lupus erythematosus.
Get full access to this article
View all access options for this article.
References
1.
TuerkC and GoldL. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249:505–510.
2.
EllingtonAD and SzostakJW. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature, 346:818–822.
3.
StoltenburgR, ReinemannC and StrehlitzB. (2007). SELEX—a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng, 24:381–403.
4.
Que-GewirthNS and SullengerBA. (2007). Gene therapy progress and prospects: RNA aptamers. Gene Ther, 14:283–291.
5.
HanK, LiangZ and ZhouN. (2010). Design strategies for aptamer-based biosensors. Sensors (Basel), 10:4541–4557.
6.
DollinsCM, NairS and SullengerBA. (2008). Aptamers in immunotherapy. Hum Gene Ther, 19:443–450.
7.
LiW, WangK, ZhaoM, YangX, ChenM and LanX. (2014). Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status. Thromb Res, 134:769–773.
8.
NgEW, ShimaDT, CaliasP, CunninghamETJr, GuyerDR and AdamisAP. (2006). Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov, 5:123–132.
9.
WhatleyAS, DitzlerMA, LangeMJ, BiondiE, SawyerAW, ChangJL, FrankenJD and BurkeDH. (2013). Potent inhibition of HIV-1 reverse transcriptase and replication by nonpseudoknot, “UCAA-motif” RNA aptamers. Mol Ther Nucleic Acids, 2:e71.
JalalianSH, TaghdisiSM, ShahidiHN, KalatSA, LavaeeP, ZandkarimiM, GhowsN, JaafariMR, NaghibiS, et al. (2013). Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci, 50:191–197.
12.
Lee MS. (2014). Role of innate immunity in the pathogenesis of type 1 and type 2 diabetes. J Korean Med Sci, 29:1038–1041.
13.
JiangG and ZhangBB. (2003). Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab, 284:E671–E678.
14.
LeeY, WangMY, DuXQ, CharronMJ and UngerRH. (2011). Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes, 60:391–397.
15.
LeeY, BerglundED, WangMY, FuX, YuX, CharronMJ, BurgessSC and UngerRH. (2012). Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci U S A, 109:14972–14976.
16.
KongHY and ByunJ. (2013). Nucleic acid aptamers: new methods for selection, stabilization, and application in biomedical science. Biomol Ther (Seoul), 21:423–434.
17.
VaterA, SellS, KaczmarekP, MaaschC, BuchnerK, Pruszynska-OszmalekE, KolodziejskiP, PurschkeWG, NowakKW, StrowskiMZ and KlussmannS. (2013). A mixed mirror-image DNA/RNA aptamer inhibits glucagon and acutely improves glucose tolerance in models of type 1 and type 2 diabetes. J Biol Chem, 288:21136–21147.
18.
ForsayethJR, MontemurroA, MadduxBA, DePirroR and GoldfineID. (1987). Effect of monoclonal antibodies on human insulin receptor autophosphorylation, negative cooperativity, and down-regulation. J Biol Chem, 262:4134–4140.
19.
DoudnaJA, CechTR and SullengerBA. (1995). Selection of an RNA molecule that mimics a major autoantigenic epitope of human insulin receptor. Proc Natl Acad Sci U S A, 92:2355–2359.
20.
LeeSW and SullengerBA. (1996). Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J Exp Med, 184:315–324.
21.
SayyedSG, HageleH, KulkarniOP, EndlichK, SegererS, EulbergD, KlussmannS and AndersHJ. (2009). Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia, 52:2445–2454.
22.
DarisipudiMN, KulkarniOP, SayyedSG, RyuM, MiglioriniA, SagrinatiC, ParenteE, VaterA, EulbergD, et al. (2011). Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol, 179:116–124.
23.
RodriguezM, SivaA, WardJ, Stolp-SmithK, O'BrienP and KurlandL. (1994). Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology, 44:28–33.
24.
BatesD. (2011). Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology, 76:S14–S25.
25.
MuramatsuT. (2002). Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem, 132:359–371.
26.
MaruyamaK, MuramatsuH, IshiguroN and MuramatsuT. (2004). Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. Arthritis Rheum, 50:1420–1429.
27.
LiuX, MashourGA, WebsterHF and KurtzA. (1998). Basic FGF and FGF receptor 1 are expressed in microglia during experimental autoimmune encephalomyelitis: temporally distinct expression of midkine and pleiotrophin. Glia, 24:390–397.
28.
VigliettaV, Baecher-AllanC, WeinerHL and HaflerDA. (2004). Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med, 199:971–979.
29.
WangJ, TakeuchiH, SonobeY, JinS, MizunoT, MiyakawaS, FujiwaraM, NakamuraY, KatoT, et al. (2008). Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population. Proc Natl Acad Sci U S A, 105:3915–3920.
30.
WarringtonAE, AsakuraK, BieberAJ, CiricB, Van KeulenV, KaveriSV, KyleRA, PeaseLR and RodriguezM. (2000). Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A, 97:6820–6825.
31.
BieberAJ, WarringtonA, AsakuraK, CiricB, KaveriSV, PeaseLR and RodriguezM. (2002). Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia, 37:241–249.
32.
Campagnoni AT. (1988). Molecular biology of myelin proteins from the central nervous system. J Neurochem, 51:1–14.
33.
NastasijevicB, WrightBR, SmestadJ, WarringtonAE, RodriguezM, MaherLJ3rd. (2012). Remyelination induced by a DNA aptamer in a mouse model of multiple sclerosis. PLoS One, 7:e39595.
34.
RodriguezM, MillerDJ and LennonVA. (1996). Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology, 46:538–545.
35.
SmestadJ, MaherLJ3rd. (2013). Ion-dependent conformational switching by a DNA aptamer that induces remyelination in a mouse model of multiple sclerosis. Nucleic Acids Res, 41:1329–1342.
36.
PerschbacherK, SmestadJA, PetersJP, StandifordMM, DenicA, WootlaB, WarringtonAE, RodriguezM, MaherLJ3rd. (2015). Quantitative PCR analysis of DNA aptamer pharmacokinetics in mice. Nucleic Acid Ther, 25:11–19.
37.
RhodesA, DeakinA, SpaullJ, CoomberB, AitkenA, LifeP and ReesS. (2000). The generation and characterization of antagonist RNA aptamers to human oncostatin M. J Biol Chem, 275:28555–28561.
38.
MajithiaV and GeraciSA. (2007). Rheumatoid arthritis: diagnosis and management. Am J Med, 120:936–939.
39.
WilliamsRO, PaleologE and FeldmannM. (2007). Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases. Curr Opin Pharmacol, 7:412–417.
40.
SalliotC, DougadosM and GossecL. (2009). Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis, 68:25–32.
41.
TagaT and KishimotoT. (1997). Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol, 15:797–819.
42.
Drachman DB. (1994). Myasthenia gravis. N Engl J Med, 330:1797–1810.
43.
GrausYF, de BaetsMH, ParrenPW, Berrih-AkninS, WokkeJ, van Breda VriesmanPJ and BurtonDR. (1997). Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J Immunol, 158:1919–1929.
44.
VenkateshN, ImSH, BalassM, FuchsS and Katchalski-KatzirE. (2000). Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide. Proc Natl Acad Sci U S A, 97:761–766.
45.
LeeSW and SullengerBA. (1997). Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies. Nat Biotechnol, 15:41–45.
46.
HwangB and LeeSW. (2002). Improvement of RNA aptamer activity against myasthenic autoantibodies by extended sequence selection. Biochem Biophys Res Commun, 290:656–662.
47.
ChoJS and LeeSW. (2009). Sequence and structural features of RNA aptamer against myasthenic autoantibodies. Oligonucleotides, 19:273–280.
48.
HwangB, HanK and LeeSW. (2003). Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer. FEBS Lett, 548:85–89.
49.
KimYM, ChoiKH, JangYJ, YuJ and JeongS. (2003). Specific modulation of the anti-DNA autoantibody-nucleic acids interaction by the high affinity RNA aptamer. Biochem Biophys Res Commun, 300:516–523.
50.
GerardC and RollinsBJ. (2001). Chemokines and disease. Nat Immunol, 2:108–115.
51.
KulkarniO, PawarRD, PurschkeW, EulbergD, SelveN, BuchnerK, NinichukV, SegererS, VielhauerV, KlussmannS and AndersHJ. (2007). Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol, 18:2350–2358.
52.
ShabgahAG, FattahiE and ShahnehFZ. (2014). Interleukin-17 in human inflammatory diseases. Postepy Dermatol Alergol, 31:256–261.
53.
IshiguroA, AkiyamaT, AdachiH, InoueJ and NakamuraY. (2011). Therapeutic potential of anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. Arthritis Rheum, 63:455–466.
54.
KeefeAD, PaiS and EllingtonA. (2010). Aptamers as therapeutics. Nat Rev Drug Discov, 9:537–550.
